A Study of Zidovudine in HIV-Infected Patients With Kidney Problems
Status:
Withdrawn
Trial end date:
1990-02-01
Target enrollment:
Participant gender:
Summary
To determine how zidovudine (AZT) for the treatment of HIV infection is metabolized and
excreted or eliminated in patients with infected or diseased kidneys. To determine the
influence of hemodialysis and establish dose guidelines.
AZT is the only antiviral agent with demonstrated effectiveness in patients with severe HIV
infection. Persons with HIV infection may have additional health problems, one of which is a
diseased kidney due to infection of the kidney, or side effects of therapy. The benefits and
risks of AZT in patients with diseased kidneys are unknown. It is hoped that this study will
allow further understanding of the metabolism and excretion of AZT in patients with kidney
disease. AZT pharmacokinetics will be studied in patients with mild, moderate, and severe
renal disorders
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)